Skip to main content

Table 1 Case Summary

From: Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

Case # Age at fingolimod cessation (Y) Sex Disease Duration (Y) Prior DMTs Treatment duration on fingolimod (Y) ALC/CD4 at the time of stopping fingolimod (cells/uL) Wash out period (W) ALC/CD4 baseline to start DMF (cells/uL) Treatment duration at time of relapse (W) ALC/CD4 at the time of relapse (cells/uL) New/Gd+ lesions at the time of relapse Response to IV steroid treatment (Yes/No)
1 37 F 10 INF-β (Rebif) 5 300/33 8 1400/ND 5 1700/615 Brain & Cervical spine Yes
2 34 F 13 GA (Copaxone) 4 282/<20 11 644/ND <1 (4 days) 626/252 Brain & Cervical spine Yes
3 33 M 3 None 3 567/61 7 1006/389 10 950/ND Brain & Cervical spine Yes
4 50 F 4 INF-β (Rebif & Plegridy) 1 270/<20 8 1000/551 14 - Brain, Cervical & Thoracic spine Yes
5 42 F 11 None 5.5 467/20 9 1036/295 13 1241/ND Brain Yes
6 33 F 8 GA (Copaxone) & INF-β (Plegridy) 1 509/<20 5 912/ND 18 1600/ND Brain & Thoracic spine Yes
  1. Absolute lymphocyte count (ALC): Normal reference range 850-3900 cells/ul (Quest Diagnostics)
  2. Absolute CD4+ lymphocyte count: Normal reference range 490-1740 cells/ul (Quest Diagnostics)
  3. ND Not done, Y Year, W Week, Gd + Lesions Gadolinium enhancing lesions